Allen Andrew R
SEC-identified person · CIK 1374539 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Cullinan Therapeutics, Inc. CGEM | Director | filed 2025–2026 |
| Adaptimmune Therapeutics PLC ADAP] | Director | filed 2023–2024 |
| Gritstone bio, Inc. GRTS | Director · President and CEO | filed 2018–2024 |
| TCR2 Therapeutics INC. TCRR | Director | filed 2019–2023 |
| Sierra Oncology, Inc. SRRA | Director | filed 2017–2022 |
| Epizyme, Inc. EPZM | Director | filed 2014–2021 |
| Clovis Oncology, Inc. CLVS | See Remarks | filed 2011–2015 |
| Pharmion Corp PHRM | Chief Medical Officer, Exec VP | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.